CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Intravitreal aflibercept injectiondrug
Likely dose
Intravitreal aflibercept injection 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02689518
NCT02689518Phase 4Completed
CompareCT.gov

Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection

University of California, San Diego·interventional·Posted Feb 24, 2016·Updated Mar 25, 2021

In Brief

A Phase 4 clinical trial evaluating Intravitreal aflibercept injection for Macular Degeneration and Wet Macular Degeneration. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration, Wet Macular Degeneration
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 24, 2016
Enrollment StartApr 1, 2014
Primary CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 10.4 years ago

Interventions

Intravitreal aflibercept injectiondrug

Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.